AML Electronic Decision Aid

Completed · Not applicable

Conditions studied: Acute Myeloid Leukemia

In brief

The purpose of this study is to test the feasibility and preliminary efficacy of a novel electronic decision aid to improve AML patients' understanding of their illness, prognosis, and treatment options.

Key facts

Study ID

NCT03442452

Run by

Duke University

People needed

20

Starts

2018-02-07

Expected to finish

2019-02-01

Last updated by the study team

2019-10-15

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• At least age 18
• Capacity to give consent
• Diagnosis of acute myeloid leukemia (AML)
• Fluent in English
• Receiving care at Duke, and fits into one of the following scenarios:
• has not yet made a treatment decision (in the DCI clinics or on the inpatient wards),
• have recently made a decision (in the last 6 weeks), and are admitted for chemotherapy on 9100 or in the oncology treatment center to receive outpatient therapy,
• or, during remission, while receiving consolidation chemotherapy in the hospital

You may not qualify if…

• Patients too sick to participate per clinician discretion

Where it is running

• Duke University Medical Center — Durham, North Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.